

# DIN ISO 13022:2014-06 (E)

## Medical products containing viable human cells - Application of risk management and requirements for processing practices (ISO 13022:2012)

---

<b>Contents</b>	<b>Page</b>
National foreword .....	3
National Annex NA (informative) Correction of Figure B.1 .....	4
National Annex N (informative) Bibliography .....	5
Introduction .....	6
1 Scope .....	7
2 Normative references .....	8
3 Terms and definitions .....	8
4 Risk management process .....	12
4.1 General .....	12
4.2 Hazards associated with the cellular component .....	12
4.3 Risk analysis .....	14
4.4 Risk evaluation .....	15
4.5 Risk control .....	15
4.6 Evaluation of overall residual risk acceptability .....	15
4.7 Production and post-production information system .....	16
Annex B (informative) Graphic representation of the part of the risk management process for cell-based medical products .....	18
Annex C (normative) Requirements for donor selection and testing .....	19
Annex D (informative) Guidance for tissue procurement .....	23
Annex E (normative) Requirements for handling of cells and tissue during manufacture .....	26
Annex F (normative) Requirements for packaging and labelling .....	29
Annex G (informative) Guidance for transport .....	32
Annex H (informative) Guidance for storage .....	37
Annex I (normative) Requirements for traceability .....	40
Annex J (normative) Risk reduction measures related to contamination with viruses and other infectious agents such as TSE .....	41
Annex K (informative) Guidance with regard to hazards caused by the tumorigenic potential of the human cells/tissues used for the production of medical products .....	44
Annex L (informative) Guidance with regard to microbiological contamination .....	45
Annex M (informative) Guidance with regard to potential adverse effects of non-cellular residues of the product .....	46

<b>Annex N (normative) Requirements with regard to potential adverse effects of the cellular components of a medical product .....</b>	<b>47</b>
<b>Annex O (informative) Guidance for the characterization of the cellular components of a medical product .....</b>	<b>48</b>
<b>Annex P (informative) Clinical evaluation and testing .....</b>	<b>51</b>
<b>Bibliography .....</b>	<b>52</b>